These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. 3-methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease. Sharpless NS; Muenter MD; Tyce GM; Owen CA Clin Chim Acta; 1972 Mar; 37():359-69. PubMed ID: 5022100 [No Abstract] [Full Text] [Related]
5. Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease. Muenter MD; Sharpless NS; Tyce GM Mayo Clin Proc; 1972 Jun; 47(6):389-95. PubMed ID: 5041685 [No Abstract] [Full Text] [Related]
6. Metabolism and absorption of L-3,4 dihydroxyphenylalanine in patients with Parkinson's disease. Bianchine JR; Calimlim LR; Morgan JP; Dujuvne CA; Lasagna L Ann N Y Acad Sci; 1971 Jul; 179():126-40. PubMed ID: 5285373 [No Abstract] [Full Text] [Related]
8. A method for the determination of dopa and 3-O-methyldopa in the plasma of Parkinsonian patients. Curzon G; Kantamaneni BD; Trigwell J Clin Chim Acta; 1972 Mar; 37():335-41. PubMed ID: 5022098 [No Abstract] [Full Text] [Related]
9. Rapid estimation of DOPA in physiological fluids using the amino acid analyzer. Hare TA; Vogel WH Biochem Med; 1970 Nov; 4(3):277-81. PubMed ID: 5524069 [No Abstract] [Full Text] [Related]
10. Effect of L-dopa on plasma free fatty acids and plasma glucose. Rivera-Calimlim L; Bianchine JR Metabolism; 1972 Jul; 21(7):611-7. PubMed ID: 5040916 [No Abstract] [Full Text] [Related]
11. Variations in L-dopa absorption. Report of a parkinsonian patient with high plasma dopa concentration after therapeutical L-dopa dose. Granerus AK; Jagenburg R; Rödjer S; Svanborg A Acta Med Scand; 1974 Dec; 196(6):459-63. PubMed ID: 4456974 [No Abstract] [Full Text] [Related]
12. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Muenter MD; Tyce GM Mayo Clin Proc; 1971 Apr; 46(4):231-9. PubMed ID: 5573818 [No Abstract] [Full Text] [Related]
13. Therapeutic implications in Parkinsonism of m-tyramine formation from L-dopa in man. Sandler M; Goodwin BL; Ruthven CR Nature; 1971 Feb; 229(5284):414-5. PubMed ID: 4926994 [No Abstract] [Full Text] [Related]
14. Plasma DOPA and growth hormone in parkinsonism: oscillations in symptoms. Papavasiliou PS; McDowell FH; Wang YY; Rosal V; Miller ST Neurology; 1979 Feb; 29(2):194-200. PubMed ID: 571063 [TBL] [Abstract][Full Text] [Related]
15. A reliable and simple method for simultaneous determination of DOPA and 3-O-methyldopa in plasma and brain. Fahn S; Prasad AL; Delesie R Anal Biochem; 1972 Apr; 46(2):557-75. PubMed ID: 4337048 [No Abstract] [Full Text] [Related]
17. Serotonin content of platelet enriched plasma in Parkinson patients prior and during treatment with L-3,4-dihydroxyphenylalanine (L-DOPA). Yamaguchi K; Tomasi L; Cote LJ; Barrett R; Yahr MD Biochem Med; 1972 Jun; 6(3):210-5. PubMed ID: 5041890 [No Abstract] [Full Text] [Related]
18. [Implications of the formulation of m-tyrosine from DOPA for Parkinsonism]. Stoof JC; Koetsier JC Ned Tijdschr Geneeskd; 1974 Jun; 118(23):900. PubMed ID: 4839449 [No Abstract] [Full Text] [Related]
19. Simultaneous measurement of DOPA and its primary metabolites in physiological fluids. Hare TA; Beasley BL; DeSimone SM; Vogel WH Biochem Med; 1974 Dec; 11(4):305-11. PubMed ID: 4429548 [No Abstract] [Full Text] [Related]
20. L-dopa in Parkinson's syndrome. Poskanzer DC N Engl J Med; 1969 Feb; 280(7):382-3. PubMed ID: 5764823 [No Abstract] [Full Text] [Related] [Next] [New Search]